[go: up one dir, main page]

IL125660A0 - Pharmaceutical composition comprising 2-(3,4-dimethoxycinnamoyl)-aminobenzoic acid for the aminobenzoic acid for the treatment or prevention of restenosis and its manufacture - Google Patents

Pharmaceutical composition comprising 2-(3,4-dimethoxycinnamoyl)-aminobenzoic acid for the aminobenzoic acid for the treatment or prevention of restenosis and its manufacture

Info

Publication number
IL125660A0
IL125660A0 IL12566097A IL12566097A IL125660A0 IL 125660 A0 IL125660 A0 IL 125660A0 IL 12566097 A IL12566097 A IL 12566097A IL 12566097 A IL12566097 A IL 12566097A IL 125660 A0 IL125660 A0 IL 125660A0
Authority
IL
Israel
Prior art keywords
aminobenzoic acid
dimethoxycinnamoyl
restenosis
prevention
manufacture
Prior art date
Application number
IL12566097A
Other languages
English (en)
Original Assignee
Kissei Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25101171&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL125660(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Kissei Pharmaceutical filed Critical Kissei Pharmaceutical
Publication of IL125660A0 publication Critical patent/IL125660A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/606—Salicylic acid; Derivatives thereof having amino groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
IL12566097A 1996-12-30 1997-12-19 Pharmaceutical composition comprising 2-(3,4-dimethoxycinnamoyl)-aminobenzoic acid for the aminobenzoic acid for the treatment or prevention of restenosis and its manufacture IL125660A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/774,418 US6019104A (en) 1996-12-30 1996-12-30 Method for the treatment or prevention of restenosis associated with coronary intervention
PCT/JP1997/004698 WO1998029104A2 (en) 1996-12-30 1997-12-19 Use of 2-(3,4-dimethoxycinnamoyl)aminobenzoic acid for the manufacture of a medicament for the treatment or prevention of restenosis

Publications (1)

Publication Number Publication Date
IL125660A0 true IL125660A0 (en) 1999-04-11

Family

ID=25101171

Family Applications (1)

Application Number Title Priority Date Filing Date
IL12566097A IL125660A0 (en) 1996-12-30 1997-12-19 Pharmaceutical composition comprising 2-(3,4-dimethoxycinnamoyl)-aminobenzoic acid for the aminobenzoic acid for the treatment or prevention of restenosis and its manufacture

Country Status (19)

Country Link
US (1) US6019104A (es)
EP (1) EP0891185A2 (es)
KR (1) KR19990087396A (es)
CN (1) CN1220599A (es)
AR (1) AR009446A1 (es)
AU (1) AU7854198A (es)
BR (1) BR9707877A (es)
CA (1) CA2247306A1 (es)
CZ (1) CZ251198A3 (es)
EA (1) EA001931B1 (es)
HU (1) HUP9904029A3 (es)
ID (1) ID20165A (es)
IL (1) IL125660A0 (es)
NO (1) NO983947D0 (es)
NZ (1) NZ331338A (es)
PE (1) PE27399A1 (es)
TR (1) TR199801698T1 (es)
WO (1) WO1998029104A2 (es)
ZA (1) ZA9711719B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1076534B1 (en) * 1998-05-05 2007-04-04 Boston Scientific Limited Stent with smooth ends
BR0007921A (pt) * 1999-02-03 2002-09-10 Smithkline Beecham Corp Processo para prevenção ou redução de eventos cardiovasculares associados com intervenção coronária
BR0007901A (pt) * 1999-02-03 2001-10-30 Smithkline Beecham Corp Método para a preservação ou redução deeventos cardiovasculares associados comintervenção coronária
WO2001062241A1 (en) * 2000-02-23 2001-08-30 Smithkline Beecham Corporation Method for the prevention or reduction of vascular access dysfunction
US20050106230A1 (en) * 2003-11-17 2005-05-19 Young Janel E. Drug-enhanced adhesion prevention

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4070484A (en) * 1973-01-18 1978-01-24 Kissei Pharmaceutical Co., Ltd. Antiallergic composition containing aromatic carboxylic amide derivatives and method of using the same
JPS5640710B2 (es) * 1973-01-18 1981-09-22
US4337270A (en) * 1980-05-21 1982-06-29 Hisamitsu Pharmaceutical Co., Inc. Novel anthranilic acid derivatives
JP2617407B2 (ja) * 1992-09-14 1997-06-04 キッセイ薬品工業株式会社 血管内膜細胞過剰増殖疾患の予防および治療剤

Also Published As

Publication number Publication date
ZA9711719B (en) 1998-06-25
NO983947D0 (no) 1998-08-27
HUP9904029A3 (en) 2000-11-28
CN1220599A (zh) 1999-06-23
ID20165A (id) 1998-10-15
CA2247306A1 (en) 1998-07-09
TR199801698T1 (xx) 1999-03-22
HUP9904029A2 (hu) 2000-05-28
NZ331338A (en) 2000-12-22
EA001931B1 (ru) 2001-10-22
WO1998029104A2 (en) 1998-07-09
EA199800781A1 (ru) 1999-12-29
WO1998029104A3 (en) 1998-10-01
PE27399A1 (es) 1999-03-31
KR19990087396A (ko) 1999-12-27
US6019104A (en) 2000-02-01
EP0891185A2 (en) 1999-01-20
AU7854198A (en) 1998-07-31
CZ251198A3 (cs) 1999-08-11
BR9707877A (pt) 1999-07-27
AR009446A1 (es) 2000-04-12

Similar Documents

Publication Publication Date Title
HUP0104425A3 (en) Anthranilic acid amides and the use thereof for the treatment of angiogenesis
HUP0103856A3 (en) Pharmaceutical composition for the treatment of acute disorders
IL146703A0 (en) Dietary of pharmaceutical composition for use for the prevention or treatment of hyperoxaluria
AU4060599A (en) Pharmaceutical composition for treating or preventing sleep disorders
IL143921A0 (en) Compositions for the treatment and prevention of tumors and tumor-related disorders
HUP9903166A3 (en) Medicinal compositions for the prophylaxis or treatment of arteriosclerosis
ZA988016B (en) Compounds methods and pharmaceutical compositions for treating neural or cardiovascular tissue damage
AU1509999A (en) Herbal drug composition for the prevention and treatment of dementia
ZA977310B (en) Transdermal propentofylline compositions for the treatment of Alzheimer's disease.
AU4133997A (en) Pharmaceutical composition for the treatment of syndrome x of reaven
AU6330799A (en) Rhodanine carboxylic acid derivatives for the treatment and prevention of metabolic bone disorders
PL345364A1 (en) The use of valproic acid analog for the treatment and prevention of migraine and affective illness
IL125660A0 (en) Pharmaceutical composition comprising 2-(3,4-dimethoxycinnamoyl)-aminobenzoic acid for the aminobenzoic acid for the treatment or prevention of restenosis and its manufacture
AU3785497A (en) Drug for the prevention or treatment of pollakiuria and urinary incontinence
GB9929497D0 (en) Improved amino acid mixtures for the treatment and/or management of certain diseases
WO2001030334A3 (en) 6-methoxy-2-naphthylacetic acid prodrugs compositions for treating inflammation
AU7653600A (en) Use of substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives for the treatment of multiple sclerosis
HUP0100957A3 (en) 5-substituted pyrimidine-2-yloxy carboxylic acid derivatives, the production of the same, their use and pharmaceutical compositions containing them
HK1018005A (en) Use of 2-(3,4-dimethoxycinnamoyl) aminobenzoic acid for the manufacture of a medicament for the treatment or prevention of restenosis
AU4103001A (en) Composition for the prevention and/or treatment of vascular diseases, comprising propionyl L-carnitine and coenzyme Q<sub>10</sub>
KR100248098B1 (en) Pharmaceutical composition for the treatment of dementia
ZA96446B (en) Use of 3,4-diphenyl chromans for the manufacture of pharmaceutical composition for the treatment or prophylaxis of obesity
HUP0200148A3 (en) Use of n-(3',4'-dimethoxy-cinnamoyl)-anthranilic acid for the prevention or reduction of cardiovascular events associated with coronary intervention
AUPP195398A0 (en) Pharmaceutical or veterinary composition for the treatment of skin disorders
IL137190A0 (en) Pharmaceutical compositions for the treatment of dyskinesias